Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Publication year range
2.
Presse Med ; 34(22 Pt 1): 1727-36, 2005 Dec 17.
Article in French | MEDLINE | ID: mdl-16374397

ABSTRACT

Psoriasis is a common dermatosis that affects 3-5% of the European population. Current treatments offer considerable clinical benefits, but their use is limited due to tolerance problems. Recent years have seen the development of new treatments, used separately or in combination to improve the chronic lesions caused by this disease. T cells play an important role in the pathogenesis of psoriasis. Various techniques target the T cells and the immunological mechanisms involved in their activation. In 2005, treatment of psoriasis is directed essentially towards immunological pathways.


Subject(s)
Psoriasis/therapy , Anti-Inflammatory Agents/therapeutic use , Dermatologic Agents/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Phototherapy , Psoriasis/physiopathology
3.
Int J Pharm ; 292(1-2): 29-41, 2005 Mar 23.
Article in English | MEDLINE | ID: mdl-15725551

ABSTRACT

The assessment of the in vitro disintegration profile of rapidly disintegrating tablets (RDT) is very important in the evaluation and the development of new formulations of this type. So far neither the US Pharmacopoeia nor the European Pharmacopoeia has defined a specific disintegration test for RDT; currently, it is only possible to refer to the tests on dispersible or effervescent tablets for the evaluation of RDT's disintegration capacity. In the present study, we have evaluated the disintegration profile of RDT manufactured by main commercialised technologies, using the texture analyser (TA). In order to simulate as much as possible the oral disintegration of these dosage forms, a new operating structure was developed. This structure mimics the situation in the patient's mouth and provides a gradual elimination of the detached particles during the disintegration process. The obtained time-distance profiles or disintegration profiles enabled the calculation of certain quantitative values as the disintegration onset (t1) and the total disintegration time (t2). These values were used in the characterisation of the effect of test variables as the disintegration medium and temperature on the disintegration time of RDT. Moreover, the oral disintegration time of the same products was evaluated by 14 healthy volunteers. Results obtained when artificial saliva at 37 degrees C was employed as disintegration medium were used to correlate the in vitro (t2) and oral disintegration times. Excellent correlation was found and in addition, we were able to achieve a qualitative measure of the mouthfeel by comparing the thickness of the tablets and the penetration distance obtained from the disintegration profile. This method also permitted the discrimination between different RDT, where differences in the disintegration mechanism were reflected on the disintegration profile achieved for each tablet.


Subject(s)
Administration, Oral , Solubility , Tablets/chemical synthesis , Drug Evaluation, Preclinical/methods , Hot Temperature , Humans , Pharmacopoeias as Topic/standards , Saliva , Tablets/analysis , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/standards , Time Factors , Water
SELECTION OF CITATIONS
SEARCH DETAIL